Get the Stockscreener App
1.68
8.20%
-0.15
After Hours:
1.66
-0.02
-1.19%
Celularity Inc stock is traded at $1.68, with a volume of 347.89K.
It is down -8.20% in the last 24 hours and up +138.84% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$1.83
Open:
$1.83
24h Volume:
347.89K
Relative Volume:
0.09
Market Cap:
$48.63M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.4688
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
+6.33%
1M Performance:
+138.84%
6M Performance:
+34.40%
1Y Performance:
-28.81%
1-Day Range:
$1.6177
$1.83
1-Week Range:
$1.38
$2.07
52-Week Range:
$0.5601
$2.55
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.68 | 22.20M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity and MuseCell Innovations Strike New Jersey Manufacturing Deal Worth Up to $300 Million - BioBuzz
Celularity and MuseCell Innovations strike US manufacturing deal with potential $300m upside & 200 jobs - Indian Pharma Post
Celularity Inc (CELUW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Celularity Manufacturing Deal Could Bring $300 Million, 200 Jobs to Florham Park - Morris Focus
Celularity (CELU) Stock News & Analysis - TechStock²
Celularity shares jump 138.5% after forecasting $300 million MuseCell manufacturing revenue - TechStock²
Celularity Partners with MuseCell Innovations to Manufacture Allogeneic Cell Therapy Products in the US - BioPharm International
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Investing News Network
Why Is Celularity Stock Gaining Thursday? - Benzinga
Florham Park Facility at Center of Cell Therapy Manufacturing Deal Worth Up to $300 Million - centraljersey.com
Celularity and MuseCell Innovations announce manufacturing collaboration - ROI-NJ
$Celularity (CELU.US)$ It's 100% happening, guys - Moomoo
Singapore's MuseCell Innovations announces manufacturing collaboration with Celularity in US - BioSpectrum Asia
Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform - tradingview.com
Celularity to manufacture Dezawa MuseCells for MuseCell Innovations By Investing.com - Investing.com India
Celularity (NASDAQ:CELU): Why Is It in Focus After It provided a fresh Nasdaq listing-compliance update? - Kalkine Media
Celularity Provides Update Regarding Nasdaq Listing Compliance - The Manila Times
Celularity Inc. Receives Nasdaq Notice for Late Quarterly Filings, Working to Regain Compliance - Quiver Quantitative
Celularity (CELU) Latest Quarter: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Shares Move Lower 2.01% on the DayDividend Earnings Report - vinanet.vn
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotPrice Momentum Stocks - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateEPS Surprise History - vinanet.vn
Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition - TipRanks
NEXGEL Q2 2026: Revenue $3.69M, Net Loss $2.87M as Company Transitions Post-Acquisition - TradingView
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (CELU) delays June 2026 10-Q filing amid liquidity and staffing strain - Stock Titan
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy - Stock Titan
CELU Q4 2025 Earnings: Narrower Loss Beats Estimates by 44.44% as Shares Rise 0.72Profit Margin Analysis - vinanet.vn
Celularity (CELU) Slips 2% as Stock Holds Between $0.66 Support and $0.72 ResistanceFast Moving Stocks - dars.gov.et
Celularity Announces Sudden Exit of Chief Commercial Officer - The Globe and Mail
Celularity Inc. Files Form 8-K as Emerging Growth Company on NASDAQ CELU Shares - Minichart
Celularity removes chief commercial officer Rick Gonzalez effective immediately - Investing.com
Form 8K Celularity Inc For: 7 August By Investing.com - Investing.com Nigeria
Celularity terminates Rick Gonzalez as Chief Commercial Officer - TradingView
Celularity (NASDAQ: CELU) terminates employment of chief commercial officer - Stock Titan
Celularity Inc Announces Termination of Rick Gonzalez from Chief Commercial Officer, Effective August 5, 2026 - marketscreener.com
Celularity Inc (CELU) Stock News Today - TradingKey
Celularity removes chief commercial officer Rick Gonzalez effective immediately By Investing.com - Investing.com Canada
Celularity Inc (CELU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celularity Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CELU|Celularity Inc|Price:0.780|Chg%:+0.030 - TradingKey
Celularity Inc (CELU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity Inc (CELU) Institutional Confidence - TradingKey
Celularity Inc (CELU) Income Statement - TradingKey
TradingKey - TradingKey
Celularity Inc. (CELU) Q4 2025 Earnings: Narrower-Than-Expected Loss as Operational Discipline ImprovesSlow Growth Warning - dars.gov.et
Philip & Daniele Barach Family Trust Net Worth (2026) - GuruFocus
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):